8 research outputs found
AORTIC VALVE REPLACEMENT USING UNSTENTED DURA OR CALF PERICARDIUM. EARLY AND LATE RESULTS
No full textAORTIC VALVE REPLACEMENT USING UNSTENTED DURA OR CALF PERICARDIUM. EARLY AND LATE RESULTS
No full textThe preparation and reactions of stable phosphorus ylides derived from maleic anhydrides, maleimides or isomaleimides
No full text
Recommended from our members
An Interview with Professor Antony Kunnan
No full textThe Web Journal Editorial Board (represented by Drew Fagan and Adrienne Wai Man Lew) had the pleasure to meet with Professor Antony Kunnan, the guest speaker of the 2010 APPLE Colloquium and Lecture, for a most in-depth discussion revolving his specialties: language testing.
Professor Kunnan is a prominent figure in language assessment. He has published widely in the field, most recently on the topic of test fairness and on assessment issues related to citizenship and immigration. Professor Kunnan is the editor of Language Assessment Quarterly, and a former President of the International Association of Language Testing.
At the end of the interview, Prof. Kunnan was thoughtful enough to have recommended several relevant book / journal titles for our further reading. To view the recommendation items, please see below.
We would like to thank Professor Kunnan for agreeing to speak with us amid his hectic schedule on the day of the Lecture. We would also like to thank Professor Jim Purpura and Catherine Box, Program Associate for Applied Linguistics, for coordinating the event. Last but not least, we would like to show our appreciation to our fellow Editorial Board member, Christos Theodoropulos, for his great ideas with regard to the interview questions
-glycosylated Proteins
No full textThe lack of antibodies with sufficient cancer selectivity is currently limiting the treatment of solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor-associated antigens that are also found in healthy tissues and often do not display sufficient cancer selectivity to be used as targets for potent antibody-based immunotherapeutic treatments, such as chimeric antigen receptor (CAR) T cells. Many solid tumors, however, display aberrant glycosylation that results in expression of tumor-associated carbohydrate antigens that are distinct from healthy tissues. Targeting aberrantly glycosylated glycopeptide epitopes within existing or novel glycoprotein targets may provide the cancer selectivity needed for immunotherapy of solid tumors. However, to date only a few such glycopeptide epitopes have been targeted. Here, we used O-glycoproteomics data from multiple cell lines to identify a glycopeptide epitope in CD44v6, a cancer-associated CD44 isoform, and developed a cancer-specific mAb, 4C8, through a glycopeptide immunization strategy. 4C8 selectively binds to Tn-glycosylated CD44v6 in a site-specific manner with low nanomolar affinity. 4C8 was shown to be highly cancer specific by IHC of sections from multiple healthy and cancerous tissues. 4C8 CAR T cells demonstrated target-specific cytotoxicity in vitro and significant tumor regression and increased survival in vivo. Importantly, 4C8 CAR T cells were able to selectively kill target cells in a mixed organotypic skin cancer model having abundant CD44v6 expression without affecting healthy keratinocytes, indicating tolerability and safety.The lack of antibodies with sufficient cancer selectivity is currently limiting the treatment of solid tumors by immunotherapies. Most current immunotherapeutic targets are tumor-associated antigens that are also found in healthy tissues and often do not display sufficient cancer selectivity to be used as targets for potent antibody-based immunotherapeutic treatments, such as chimeric antigen receptor (CAR) T cells. Many solid tumors, however, display aberrant glycosylation that results in expression of tumor-associated carbohydrate antigens that are distinct from healthy tissues. Targeting aberrantly glycosylated glycopeptide epitopes within existing or novel glycoprotein targets may provide the cancer selectivity needed for immunotherapy of solid tumors. However, to date only a few such glycopeptide epitopes have been targeted. Here, we used O-glycoproteomics data from multiple cell lines to identify a glycopeptide epitope in CD44v6, a cancer-associated CD44 isoform, and developed a cancer-specific mAb, 4C8, through a glycopeptide immunization strategy. 4C8 selectively binds to Tn-glycosylated CD44v6 in a site-specific manner with low nanomolar affinity. 4C8 was shown to be highly cancer specific by IHC of sections from multiple healthy and cancerous tissues. 4C8 CAR T cells demonstrated target-specific cytotoxicity in vitro and significant tumor regression and increased survival in vivo. Importantly, 4C8 CAR T cells were able to selectively kill target cells in a mixed organotypic skin cancer model having abundant CD44v6 expression without affecting healthy keratinocytes, indicating tolerability and safety.</p
